Accelerating Product Innovation and Availability

Improving how prevention is delivered

Developing a rich pipeline of options for HIV prevention is essential and must be guided by community priorities that define what products are needed and supported through R&D.

Once approved, interventions typically become widely available in wealthy countries within a few years time. But scaling up new options in lower and middle-income countries lags for years, even decades, with devastating effects on global health, individual lives, and the global effort to end the epidemic.

AVAC’s work supports:

The Latest on Accelerating Product Innovation

Event

The Fight for Health Justice in an Age of Retreat

Hard-won gains in access to essential medicines, vaccines, and diagnostics are under siege from political retreat, corporate profiteering, and deadly funding cuts. Yet governments building local production and increasing domestic health investment, multilateral initiatives expanding pooled procurement and financing, and civil society breaking drug monopolies prove that progress is possible when lives are valued over profits. This event will chart how the world can keep advancing access to medicines—because retreat is not an option.

Press Release

AVAC Applauds Agreements to Accelerate Market Development for Lenacapavir for PrEP

AVAC welcomes parallel announcements from the Gates Foundation and Unitaid on strategic investments to accelerate the development of, access to and price reduction for generic versions of injectable lenacapavir (LEN), the highly effective six-monthly injection for HIV PrEP.

Event

South African AIDS Conference (SAAIDS)

The 12th SAAIDS Conference 2025, under the theme: Unite for Change – Empower Communities and Redefine Priorities for HIV/AIDS will be held in Johannesburg 8-11 September.